124 related articles for article (PubMed ID: 37664946)
21. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
22.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
23. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
24. Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
[TBL] [Abstract][Full Text] [Related]
25. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
26. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
[TBL] [Abstract][Full Text] [Related]
27. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.
Montavon G; Jauquier N; Coulon A; Peuchmaur M; Flahaut M; Bourloud KB; Yan P; Delattre O; Sommer L; Joseph JM; Janoueix-Lerosey I; Gross N; Mühlethaler-Mottet A
Oncotarget; 2014 Jun; 5(12):4452-66. PubMed ID: 24947326
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
29. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
30. [ALK gene mutations in childhood neuroblastoma].
Yang CL; Yue LJ; Jiang XP; Wen FQ; Zheng MM
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):763-6. PubMed ID: 23092569
[TBL] [Abstract][Full Text] [Related]
31. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
[TBL] [Abstract][Full Text] [Related]
34. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
36. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
[TBL] [Abstract][Full Text] [Related]
37. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
38. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
39. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
Chen S; Zhou C; Ma X; Gong L
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
[TBL] [Abstract][Full Text] [Related]
40. Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Andolfo I; Lasorsa VA; Manna F; Rosato BE; Formicola D; Iolascon A; Capasso M
J Cell Mol Med; 2020 Jun; 24(11):6459-6471. PubMed ID: 32336043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]